Hi Stayso,
Noxopharm board has acknowledged the delay in the trials see below.
December 2021 Quarterly Activities Report and Appendix 4C
Lockdowns and the emergence of the Omicron variant have had a significant impact on hospital
workforces worldwide, inevitably impacting the availability of hospital resources to conduct clinical
trials. Nevertheless, Noxopharm is confident that it will meet its budgeted timelines for full patient
recruitment across all 3 trials
Ann: March 2022 Quarterly Activities Report and Appendix 4C, page-41
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.010(9.52%) |
Mkt cap ! $33.60M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 14.0¢ | 11.0¢ | $559.0K | 4.481M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6612 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 99714 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |